Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Current Size And Growth Outlook For The Next Generation Drug Conjugates Market?

In recent times, the market size for next-generation drug conjugates has seen a significant expansion. It’s projected to rise from $2.15 billion in 2024 to $2.47 billion in 2025, boasting a compound annual growth rate (CAGR) of 14.8%. Various factors have contributed to this notable growth in the historical period including enhanced comprehension of tumor biology, the triumph of initial drug conjugates, an uptick in oncology, escalated investment and funding, and heightened patient advocacy and awareness.

In the coming years, the market size of next-generation drug conjugates is poised for swift expansion, with predictions of it reaching $4.41 billion in 2029 with a compound annual growth rate (CAGR) of 15.6%. Several factors account for the anticipated growth during the forecast period, including the proliferation of combination therapies, the widening scope of clinical research, increased attention to rare diseases, strategic partnerships, and the emergence of bioinformatics tools. The forecast period could also see prevailing trends like progress in monoclonal antibody technology, the pairing of treatments with JAK inhibitors, the application of artificial intelligence in drug discovery, the creation of biosimilars, and advancements in subcutaneous formulations.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp

What External And Internal Drivers Are Influencing The Next Generation Drug Conjugates Market?

Increasing cancer rates are predicted to boost the expansion of the next-generation drug conjugates market. Cancer constitutes a range of diseases identified by unrestrained proliferation and distribution of abnormal cells within the body. The surge in cancer instances predominantly stems from an aging demographic, lifestyle-associated factors, environmental exposures, enhanced detection, genetic components, and infectious agents. Next-generation drug conjugates can counteract cancer by transporting targeted treatments straight to cancerous cells, elevating the effectiveness of the treatment whilst reducing harm to healthy tissue. As an example, a report published by Australia-based national health and welfare statistics agency, the Australian Institute of Health and Welfare in August 2024, forecasted that by 2034, roughly 209,000 new diagnoses of cancer would occur in Australia, markedly up from the anticipated 169,000 cases in 2024. This upward trend highlights the effect of a burgeoning population coupled with escalating cancer rates. Consequently, the upward trajectory of cancer prevalence is fuelling the growth of the next-generation drug conjugates market.

What Are The Key Segment Trends Observed In The Next Generation Drug Conjugates Market?

The next generation drug conjugates market covered in this report is segmented –

1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate

2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles

3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule

4) By Therapy: Monotherapy, Combination Therapy

5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications

Subsegments:

1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides

2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates

3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates

4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates

Which Disruptive Trends Are Driving Change Across The Next Generation Drug Conjugates Market?

Leading firms in the next-generation drug conjugates market are employing strategic partnership strategies to bolster their research and development capabilities, hasten product innovation, and increase their market footprint. Strategic partnerships entail a process where firms capitalize on each other’s strengths and resources for shared success and benefits. For example, in November 2023, Prelude Therapeutics Incorporated, a precision oncology company based in the US, formed a strategic alliance with AbCellera Biologics Inc., a biotech firm from Canada, to develop pioneering precision antibody-drug conjugates (ADCs) for oncology. The focus of this partnership is the discovery, creation, and marketing of novel antibody-drug conjugates (ADCs), commencing with a project that aims at a SMARCA degrader linked with a new antibody. The intention of this tactic is to extend the therapeutic uses of Prelude’s SMARCA2 selective degraders to a broader patient demographic, especially to those suffering from cancers that do not have SMARCA4 mutations.

Who Are The Leading Companies Driving The Next Generation Drug Conjugates Market?

Major companies operating in the next generation drug conjugates marker are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/next-generation-drug-conjugates-global-market-report

Which Region Is Forecasted To Lead The Next Generation Drug Conjugates Market In The Coming Years?

North America was the largest region in the next generation drug conjugates market in 2024. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=19124&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model